FAILURE OF THALIDOMIDE TO INHIBIT TUMOR-GROWTH AND ANGIOGENESIS IN-VIVO

Thalidomide was recently suggested to be an angiogenesis-inhibitor fol lowing the demonstration of its activity in a rabbit cornea micropocke t model. The purpose of the present study was to test its efficacy in solid tumors in mice. B16-F10 melanoma and CT-26 colon carcinoma cells were injected subcutaneously, intravenously and intraperitoneally, an d mice received daily gavage of 0.3-1.0 mg thalidomide starting either two or 10 days following tumor cell injection. The tumors were measur ed and compared with controls. There was to growth retardation in CT-2 6 bearing mice nor in mice with pulmonary or peritoneal metastases of B16-F10 melanoma. In 3/7 groups of mice with SC B16-F10 tumors, growth retardation was demonstrated, however the difference was not statisti cally significant. All tumors eventually reached maximal size, similar to controls. Morphological evaluation of the blood vessels oriented t owards the tumor revealed that in both thalidomide and control groups, all mice had developed an intact network of new blood vessels. In our model for the oral administration of thalidomide inhibition of tumor growth and angiogenesis did not occur. We hypothesize that the lack of sustained antiangiogenic response was either due to immune modulation or to tumor heterogeneity and adaptation.